首页 | 本学科首页   官方微博 | 高级检索  
检索        

非小细胞肺癌中特异性富 AT 序列结合蛋白 1( SATB1) 的差异性表达及其与临床和预后的关系
引用本文:陈应泰,黄宇清,金璐明,崔健,刘强,刘军,王俊.非小细胞肺癌中特异性富 AT 序列结合蛋白 1( SATB1) 的差异性表达及其与临床和预后的关系[J].现代肿瘤医学,2014(3):555-558.
作者姓名:陈应泰  黄宇清  金璐明  崔健  刘强  刘军  王俊
作者单位:[1]北京市海淀医院胸外科,北京100080 [2]北京大学人民医院胸外科暨胸部微创中心,北京100044
基金项目:北京市优秀人才培养资助项目(编号:PYZZ090416001053)
摘    要:目的:研究特异性富AT序列结合蛋白1(SATB1)在非小细胞肺癌(NSCLC)和正常肺组织中的差异性表达及其与临床、病理特征和预后之间的关系.方法:2008年8月至2009年12月间于我科接受手术治疗的60例NSCLC患者的60对NSCLC和癌旁正常肺组织标本,以实时定量RNA反转录聚合酶链式反应(real-time RT-PCR)验证SATB1在肺癌和正常肺组织间是否存在差异性表达.按SATB1基因表达量是否高于均值而将患者分为SATB1高、低表达两组,分析SATB1表达程度高低与NSCLC的病理类型、pTNM分期、无瘤生存时间(DFS)、总生存时间(OS)之间的关系.结果:SATB1 基因在NSCLC中的表达高于癌旁正常肺组织(P<0.001).该基因的表达程度与肺癌患者性别 (P=0.155)、病理类型(P=0.809)、肿瘤分化程度(P=0.937)以及病理分期(P=0.704)之间无明显相关性.2例患者失访,余58例患者中位随访时间44个月(4-58个月).SATB1高、低表达组患者的3年无瘤生存率分别为33.7%和42.9%;中位DFS分别为18个月和28个月;3年总生存率分别为38.8%和71.4%,高表达组中位OS 21个月,低表达组中位OS未达到.结论:SATB1在肺癌组织中的表达高于正常肺组织,肺癌组织中SATB1高表达组患者的预后较低表达组为差.

关 键 词:SATB1  非小细胞肺癌  基因表达  多聚酶链反应  预后

Differential expression of gene SATB1 and its relationship with clinical and prognostic features of lung cancer
Chen Yingtai,Huang Yuqing,Jin Luming,Cui Jian,Liu Qiang,Liu Jun,Wang Jun.Differential expression of gene SATB1 and its relationship with clinical and prognostic features of lung cancer[J].Journal of Modern Oncology,2014(3):555-558.
Authors:Chen Yingtai  Huang Yuqing  Jin Luming  Cui Jian  Liu Qiang  Liu Jun  Wang Jun
Institution:1 Department of Thoracic Surgery, Beijing Haidian Hospital, Beijing 100080, China ; 2 Department of Thoracic Surgery, Peking University People's Hospital, Beijing 100044, China.)
Abstract:Objectlve:To investigate the relationship between the expression of SATB1 (special AT - rich se- quence binding protein 1) ,and the stage, pathologic styles and prognosis of the patients suffered from non - small cell lung cancer (NSCLC). Methods:Total of 60 couples of samples of NSCLC and normal tissues nearby were used. Real - time quantitative RT - PCR was performed to eoufirrn the differential expression of SATB1 in the two different sam- ples. Then the relationship between the SATB1 expression level and the clinical and prognostic features of NSCLC,such as pathologic styles, pTNM stages, overall smwival (OS) and disease -free smwival (DFS) ,were studied. Re- sults: Expression of the gene SATB1 was higher in NSCLC than in the adjacent normal tissues (P 〈 0. 001). Expres- sion level of SATB1 was not related to gender (P=0.155) ,pathologic styles (P=0. 809) ,tumor differentiation (P=0.937) and tmnor stage (P=0. 704). The median follow - up time of 58 patients was 44 months (4 - 58 months). The 3 - year OS and DFS for the higher expression level group and for the lower expression level group were 38.8% ,33.7% and 71.4% ,42.9%. The medimn DFS for the higher and lower expression level groups were 18 and 28 months respectively. Conclusion: SATB1 is differentially higher expressed in the NSCLC tissue than that in the normal tissue,the prognosis of the higher SATB1 expression level patients were worse than that of the lower level pa- tients.
Keywords:SATB1  non - small cell lung cancer  gene expression  real - time quantitative RT - PCR  prognosis
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号